Display options
Cite
Muntasell A, Cabo M, Servitja S, et al. Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. Front Immunol. 2017;8:1544doi: 10.3389/fimmu.2017.01544.
Muntasell, A., Cabo, M., Servitja, S., Tusquets, I., Martínez-García, M., Rovira, A., Rojo, F., Albanell, J., & López-Botet, M. (2017). Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. Frontiers in immunology, 81544. https://doi.org/10.3389/fimmu.2017.01544
Muntasell, Aura, et al. "Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy." Frontiers in immunology vol. 8 (2017): 1544. doi: https://doi.org/10.3389/fimmu.2017.01544
Muntasell A, Cabo M, Servitja S, Tusquets I, Martínez-García M, Rovira A, Rojo F, Albanell J, López-Botet M. Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. Front Immunol. 2017 Nov 13;8:1544. doi: 10.3389/fimmu.2017.01544. eCollection 2017. PMID: 29181007; PMCID: PMC5694168.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2017 Nov 13;8:1544. doi: 10.3389/fimmu.2017.01544. eCollection 2017.

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.

Frontiers in immunology

Aura Muntasell, Mariona Cabo, Sonia Servitja, Ignasi Tusquets, María Martínez-García, Ana Rovira, Federico Rojo, Joan Albanell, Miguel López-Botet

Affiliations

  1. Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
  2. Department of Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain.
  3. Hospital Fundación Jiménez Díaz, Madrid, Spain.
  4. Univ. Pompeu Fabra, Barcelona, Spain.

PMID: 29181007 PMCID: PMC5694168 DOI: 10.3389/fimmu.2017.01544

Abstract

Overexpression of the human epidermal growth factor receptor 2 (HER2) defines a subgroup of breast tumors with aggressive behavior. The addition of HER2-targeted antibodies (i.e., trastuzumab, pertuzumab) to chemotherapy significantly improves relapse-free and overall survival in patients with early-stage and advanced disease. Nonetheless, considerable proportions of patients develop resistance to treatment, highlighting the need for additional and co-adjuvant therapeutic strategies. HER2-specific antibodies can trigger natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity and indirectly enhance the development of tumor-specific T cell immunity; both mechanisms contributing to their antitumor efficacy in preclinical models. Antibody-dependent NK cell activation results in the release of cytotoxic granules as well as the secretion of pro-inflammatory cytokines (i.e., IFNγ and TNFα) and chemokines. Hence, NK cell tumor suppressive functions include direct cytolytic killing of tumor cells as well as the regulation of subsequent antitumor adaptive immunity. Albeit tumors with gene expression signatures associated to the presence of cytotoxic lymphocyte infiltrates benefit from trastuzumab-based treatment, NK cell-related biomarkers of response/resistance to HER2-specific therapeutic antibodies in breast cancer patients remain elusive. Several variables, including (i) the configuration of the patient NK cell repertoire; (ii) tumor molecular features (i.e., estrogen receptor expression); (iii) concomitant therapeutic regimens (i.e., chemotherapeutic agents, tyrosine kinase inhibitors); and (iv) evasion mechanisms developed by progressive breast tumors, have been shown to quantitatively and qualitatively influence antibody-triggered NK cell responses. In this review, we discuss possible interventions for restoring/enhancing the therapeutic activity of HER2 therapeutic antibodies by harnessing NK cell antitumor potential through combinatorial approaches, including immune checkpoint blocking/stimulatory antibodies, cytokines and toll-like receptor agonists.

Keywords: antibody-dependent cell-mediated cytotoxicity; breast cancer; human epidermal growth factor receptor 2; immunotherapy; natural killer cells; pertuzumab; trastuzumab

References

  1. J Immunol. 2017 Jan 1;198(1):94-101 - PubMed
  2. Cancer Treat Rev. 2013 Dec;39(8):925-34 - PubMed
  3. Cancer Immunol Res. 2014 Oct;2(10):962-9 - PubMed
  4. Oncotarget. 2014 Aug 30;5(16):6633-46 - PubMed
  5. Nat Immunol. 2016 Aug 19;17 (9):1025-36 - PubMed
  6. Nat Med. 2008 May;14(5):518-27 - PubMed
  7. PLoS One. 2012;7(6):e39170 - PubMed
  8. Adv Immunol. 2014;122:91-128 - PubMed
  9. J Immunol. 2005 Aug 1;175(3):1619-27 - PubMed
  10. Am J Clin Pathol. 2015 Oct;144(4):570-8 - PubMed
  11. Oncoimmunology. 2012 Oct 1;1(7):1104-1110 - PubMed
  12. Oncogene. 2007 Jun 14;26(28):4106-14 - PubMed
  13. J Immunol. 2003 Sep 1;171(5):2366-73 - PubMed
  14. J Exp Med. 2009 Jul 6;206(7):1495-503 - PubMed
  15. Blood. 2004 Dec 1;104(12):3664-71 - PubMed
  16. J Allergy Clin Immunol. 2017 Jan;139(1):335-346.e3 - PubMed
  17. Breast Cancer Res Treat. 2009 Sep;117(1):83-9 - PubMed
  18. Curr Top Microbiol Immunol. 2016;395:115-45 - PubMed
  19. J Immunother. 2011 Apr;34(3):270-8 - PubMed
  20. Anticancer Res. 2011 Sep;31(9):2999-3005 - PubMed
  21. Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7142-7 - PubMed
  22. Eur J Gynaecol Oncol. 2010;31(1):90-3 - PubMed
  23. J Immunol. 2012 Mar 1;188(5):2136-45 - PubMed
  24. Sci Signal. 2016 Feb 16;9(415):ra19 - PubMed
  25. Nat Rev Immunol. 2005 Mar;5(3):201-14 - PubMed
  26. Mol Cancer Ther. 2009 Nov;8(11):2983-91 - PubMed
  27. Cancer Cell. 2010 Aug 9;18(2):160-70 - PubMed
  28. Immunogenetics. 1994;39(3):161-7 - PubMed
  29. Cancer Discov. 2015 Sep;5(9):915-9 - PubMed
  30. Nat Rev Clin Oncol. 2016 Apr;13(4):228-41 - PubMed
  31. Cell. 2003 Apr 18;113(2):207-19 - PubMed
  32. Oncotarget. 2014 Nov 30;5(22):10963-4 - PubMed
  33. Lancet Oncol. 2012 Jan;13(1):25-32 - PubMed
  34. J Exp Med. 2012 Sep 24;209(10):1869-82 - PubMed
  35. Clin Cancer Res. 2004 May 15;10(10):3401-9 - PubMed
  36. Semin Oncol. 2015 Aug;42(4):640-55 - PubMed
  37. Oncotarget. 2016 Jan 5;7(1):255-65 - PubMed
  38. Immunol Rev. 2006 Dec;214:155-60 - PubMed
  39. Oncoimmunology. 2015 May 29;4(12):e1052353 - PubMed
  40. Front Immunol. 2014 Jan 07;4:508 - PubMed
  41. Immunity. 2016 Aug 16;45(2):280-91 - PubMed
  42. Nat Rev Immunol. 2016 Feb;16(2):112-23 - PubMed
  43. J Exp Med. 2006 Feb 20;203(2):289-95 - PubMed
  44. JAMA Oncol. 2017 Mar 1;3(3):335-341 - PubMed
  45. Curr Opin Immunol. 2017 Apr;45:73-81 - PubMed
  46. PLoS Pathog. 2014 Mar 20;10(3):e1004011 - PubMed
  47. Science. 1987 Jan 9;235(4785):177-82 - PubMed
  48. N Engl J Med. 2005 Oct 20;353(16):1734-6 - PubMed
  49. Oncoimmunology. 2015 Apr 1;4(10):e1022301 - PubMed
  50. Cancer Immunol Res. 2015 Mar;3(3):219-27 - PubMed
  51. Sci Transl Med. 2015 Nov 25;7(315):315ra188 - PubMed
  52. Front Immunol. 2016 Dec 05;7:561 - PubMed
  53. Cancer Immunol Immunother. 2009 May;58(5):653-64 - PubMed
  54. Blood. 2013 May 2;121(18):3599-608 - PubMed
  55. Front Immunol. 2017 Jun 12;8:675 - PubMed
  56. Clin Cancer Res. 2016 Nov 1;22(21):5183-5188 - PubMed
  57. Immunity. 2007 Dec;27(6):965-74 - PubMed
  58. Breast. 2016 Oct;29:241-50 - PubMed
  59. J Clin Invest. 2011 Sep;121(9):3609-22 - PubMed
  60. Cancer Res. 2006 Jan 1;66(1):517-26 - PubMed
  61. Oncotarget. 2016 Nov 8;7(45):73830-73844 - PubMed
  62. Nat Immunol. 2014 May;15(5):431-8 - PubMed
  63. Crit Rev Oncog. 2012;17(1):1-16 - PubMed
  64. Lancet Oncol. 2014 Feb;15(2):e58-68 - PubMed
  65. Nat Med. 1997 Jun;3(6):682-5 - PubMed
  66. J Immunol Res. 2016;2016:4684268 - PubMed
  67. Breast Cancer Res. 2011;13(6):R123 - PubMed
  68. Cancer Res. 2009 Dec 15;69(24):9330-6 - PubMed
  69. Blood. 2005 Jul 1;106(1):338-44 - PubMed
  70. Clin Cancer Res. 2013 Apr 1;19(7):1858-72 - PubMed
  71. Breast Cancer Res Treat. 2017 Feb;162(1):19-30 - PubMed
  72. J Biol Chem. 2000 Feb 25;275(8):5867-73 - PubMed
  73. Cancer Gene Ther. 2005 Mar;12(3):228-37 - PubMed
  74. Oncotarget. 2016 Mar 29;7(13):16130-45 - PubMed
  75. Front Immunol. 2015 Mar 04;6:97 - PubMed
  76. PLoS One. 2007 Mar 28;2(3):e326 - PubMed
  77. Clin Cancer Res. 2004 Apr 1;10(7):2538-44 - PubMed
  78. J Exp Med. 2002 Feb 4;195(3):343-51 - PubMed
  79. Vaccines (Basel). 2014 Apr 25;2(2):323-53 - PubMed
  80. Cancer Res. 2011 Nov 1;71(21):6621-32 - PubMed
  81. Blood. 2010 Sep 30;116(13):2286-94 - PubMed
  82. Cancer Discov. 2016 Apr;6(4):414-29 - PubMed
  83. Cancer Immunol Res. 2015 Jul;3(7):704-13 - PubMed
  84. EMBO J. 2004 Jan 28;23(2):255-9 - PubMed
  85. Oncoimmunology. 2015 Mar 2;4(4):e1008866 - PubMed
  86. Haematologica. 2014 Jun;99(6):e81-3 - PubMed
  87. Lancet Oncol. 2017 Jun;18(6):732-742 - PubMed
  88. Semin Cancer Biol. 2007 Dec;17(6):459-68 - PubMed
  89. Clin Cancer Res. 2004 May 15;10(10):3542-51 - PubMed
  90. Blood. 1997 Aug 1;90(3):1109-14 - PubMed
  91. Front Immunol. 2017 Mar 31;8:304 - PubMed
  92. Leukemia. 2007 Feb;21(2):356-9; author reply 359 - PubMed
  93. J Immunol. 2017 Jul 15;199(2):656-665 - PubMed
  94. Blood. 2008 Aug 1;112(3):699-707 - PubMed
  95. Nat Med. 2000 Apr;6(4):443-6 - PubMed
  96. Int J Cancer. 1994 Dec 1;59(5):646-56 - PubMed
  97. Clin Cancer Res. 2011 Aug 1;17 (15):5060-70 - PubMed
  98. Br J Cancer. 2002 Jul 1;87(1):21-7 - PubMed
  99. Nat Immunol. 2016 Jul;17 (7):816-24 - PubMed
  100. Cancer Res. 2014 Oct 15;74(20):5746-57 - PubMed
  101. Breast Cancer Res Treat. 2014 Jul;146(1):15-24 - PubMed
  102. Oncoimmunology. 2016 Jul 11;5(8):e1207841 - PubMed
  103. Eur J Immunol. 2001 Oct;31(10):3016-25 - PubMed
  104. Cancer Res. 2017 Jan 15;77(2):312-319 - PubMed
  105. Oncotarget. 2017 Jan 10;8(2):2731-2744 - PubMed
  106. Oncotarget. 2015 Mar 10;6(7):5449-64 - PubMed
  107. J Immunol. 2015 Aug 15;195(4):1676-84 - PubMed
  108. Breast Cancer Res. 2015 May 23;17:71 - PubMed
  109. Clin Cancer Res. 2007 Sep 1;13(17):5133-43 - PubMed
  110. Front Immunol. 2017 Feb 16;8:166 - PubMed
  111. J Immunol. 2015 Mar 15;194(6):2715-24 - PubMed
  112. Cancer Res. 2016 Jan 15;76(2):264-74 - PubMed
  113. J Clin Oncol. 2015 Mar 1;33(7):701-8 - PubMed
  114. Am J Transl Res. 2016 Feb 15;8(2):473-84 - PubMed
  115. J Clin Invest. 2014 Jun;124(6):2668-82 - PubMed
  116. Immunity. 2006 Aug;25(2):331-42 - PubMed
  117. Cell. 2015 May 21;161(5):1035-1045 - PubMed
  118. Cancer Immunol Immunother. 2017 Oct;66(10 ):1367-1375 - PubMed
  119. Cancer Res. 2002 Nov 1;62(21):6178-86 - PubMed
  120. Mod Pathol. 2011 Mar;24(3):367-74 - PubMed
  121. Lancet. 2000 Nov 25;356(9244):1795-9 - PubMed
  122. J Leukoc Biol. 2016 Jan;99(1):87-96 - PubMed
  123. J Immunol. 2011 Mar 15;186(6):3401-9 - PubMed
  124. Nat Med. 2014 Nov;20(11):1301-9 - PubMed
  125. Cancer Res. 2014 Jul 1;74(13):3429-40 - PubMed
  126. Trends Immunol. 2012 Aug;33(8):406-12 - PubMed
  127. Clin Cancer Res. 2016 Jul 15;22(14 ):3440-50 - PubMed
  128. Clin Cancer Res. 2016 Jul 1;22(13):3249-59 - PubMed
  129. Breast Cancer Res. 2012 Oct 01;14(5):R129 - PubMed
  130. J Transl Med. 2008 May 16;6:25 - PubMed
  131. Cancer Res. 2006 Jan 1;66(1):563-70 - PubMed
  132. Cancer Immunol Immunother. 2005 May;54(5):468-76 - PubMed
  133. Cancer Res. 2007 Dec 15;67(24):11991-9 - PubMed
  134. Oncol Lett. 2017 Aug;14 (2):2405-2409 - PubMed
  135. Eur J Immunol. 2013 Dec;43(12):3268-78 - PubMed
  136. Eur J Immunol. 2003 Oct;33(10):2727-35 - PubMed
  137. Clin Proteomics. 2011 Jun 09;8(1):9 - PubMed
  138. Clin Cancer Res. 2011 Jan 1;17 (1):67-76 - PubMed
  139. Int J Cancer. 2011 May 1;128(9):2125-37 - PubMed
  140. Cancer Res. 2004 Jan 1;64(1):215-20 - PubMed
  141. Cancer J. 2013 Nov-Dec;19(6):483-9 - PubMed
  142. Immunotherapy. 2012 May;4(5):511-27 - PubMed
  143. Cancer Immunol Immunother. 2004 Oct;53(10):904-10 - PubMed
  144. Curr Opin Immunol. 1998 Jun;10(3):259-64 - PubMed
  145. Cancer Res. 2017 Oct 1;77(19):5374-5383 - PubMed
  146. Lancet. 2012 Feb 18;379(9816):633-40 - PubMed
  147. Br J Cancer. 2006 Jan 30;94(2):259-67 - PubMed
  148. Eur J Immunol. 2014 Jun;44(6):1582-92 - PubMed
  149. Clin Cancer Res. 2009 Dec 15;15(24):7479-7491 - PubMed
  150. J Immunol. 2010 Dec 15;185(12):7452-9 - PubMed
  151. Curr Opin Immunol. 2007 Apr;19(2):239-45 - PubMed
  152. Clin Cancer Res. 2004 Sep 1;10(17):5650-5 - PubMed
  153. J Clin Invest. 2002 Oct;110(7):983-92 - PubMed
  154. Clin Cancer Res. 2012 Jan 15;18(2):499-509 - PubMed
  155. J Clin Oncol. 2008 Apr 10;26(11):1789-96 - PubMed
  156. Int J Cancer. 2006 Feb 1;118(3):684-7 - PubMed
  157. Clin Cancer Res. 2016 Jan 15;22(2):337-45 - PubMed
  158. Oncogene. 2009 Feb 12;28(6):803-14 - PubMed
  159. Crit Rev Oncog. 2014;19(1-2):91-105 - PubMed
  160. Immunol Rev. 2015 Sep;267(1):197-213 - PubMed
  161. Immunol Rev. 2015 Sep;267(1):178-96 - PubMed
  162. Nat Med. 2011 Jun;17(6):700-7 - PubMed
  163. Cancer Res. 2016 Jul 1;76(13):3702-10 - PubMed
  164. Immunol Rev. 2006 Dec;214:73-91 - PubMed
  165. Cancer Cell. 2015 Apr 13;27(4):489-501 - PubMed
  166. Nat Rev Immunol. 2002 Dec;2(12):957-64 - PubMed
  167. Nature. 2012 Mar 25;484(7395):529-33 - PubMed
  168. Cancer Res. 2008 Aug 1;68(15):6368-76 - PubMed
  169. J Transl Med. 2015 Jun 27;13:204 - PubMed
  170. Oncoimmunology. 2015 Oct 29;5(4):e1100790 - PubMed
  171. Clin Cancer Res. 2016 Nov 1;22(21):5211-5222 - PubMed
  172. Ann Oncol. 2017 Apr 1;28(4):855-861 - PubMed
  173. Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17858-63 - PubMed
  174. Cancer Immunol Immunother. 2014 May;63(5):419-35 - PubMed
  175. Clin Cancer Res. 2003 Jul;9(7):2440-6 - PubMed
  176. Curr Top Dev Biol. 2015;112:197-231 - PubMed
  177. Blood. 2013 Apr 4;121(14):2678-88 - PubMed
  178. Proc Natl Acad Sci U S A. 1989 Nov;86(21):8289-93 - PubMed
  179. J Immunol. 2013 Mar 1;190(5):2424-36 - PubMed
  180. Cancer Cell. 2017 Aug 14;32(2):135-154 - PubMed
  181. Trends Immunol. 2013 Apr;34(4):182-91 - PubMed
  182. Nat Immunol. 2008 May;9(5):495-502 - PubMed
  183. Oncotarget. 2016 Nov 8;7(45):72961-72977 - PubMed
  184. Cell Rep. 2017 May 9;19(6):1189-1201 - PubMed
  185. Hematol Oncol Clin North Am. 2006 Jun;20(3):585-612 - PubMed
  186. Oncogene. 2007 Oct 4;26(45):6469-87 - PubMed
  187. Int J Cancer. 2004 Jan 1;108(1):71-7 - PubMed
  188. Leukemia. 2016 Feb;30(2):456-63 - PubMed
  189. Blood. 2013 Feb 21;121(8):1326-34 - PubMed
  190. J Hematol Oncol. 2013 Jan 04;6:1 - PubMed
  191. Clin Cancer Res. 2012 Jun 15;18(12):3478-86 - PubMed
  192. Annu Rev Immunol. 2001;19:197-223 - PubMed
  193. J Clin Invest. 2012 Mar;122(3):1066-75 - PubMed
  194. J Clin Oncol. 2015 Jan 1;33(1):74-82 - PubMed
  195. Breast Cancer Res. 2002;4(5):R9 - PubMed
  196. Annu Rev Immunol. 2002;20:217-51 - PubMed
  197. Semin Immunol. 2014 Apr;26(2):152-60 - PubMed
  198. J Exp Med. 2003 Aug 18;198(4):557-67 - PubMed
  199. Nat Rev Immunol. 2008 Jan;8(1):34-47 - PubMed

Publication Types

Grant support